Charles Schwab’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,181,661
| Closed | -$85.2M | – | 3508 |
|
|
2025
Q4 | $85.2M | Buy |
1,181,661
+57,884
| +5% | +$3.74M | 0.01% | 806 |
|
|
2025
Q3 | $49M | Buy |
1,123,777
+75,558
| +7% | +$3.05M | 0.01% | 1182 |
|
|
2025
Q2 | $29.8M | Buy |
1,048,219
+24,641
| +2% | +$734K | 0.01% | 1437 |
|
|
2025
Q1 | $30.2M | Sell |
1,023,578
-5,353
| -0.5% | -$167K | 0.01% | 1392 |
|
|
2024
Q4 | $29.9M | Buy |
1,028,931
+38,749
| +4% | +$1.62M | 0.01% | 1458 |
|
|
2024
Q3 | $45.5M | Buy |
990,182
+197,065
| +25% | +$8.55M | 0.01% | 1187 |
|
|
2024
Q2 | $32.4M | Buy |
793,117
+244,682
| +45% | +$7.02M | 0.01% | 1361 |
|
|
2024
Q1 | $14M | Buy |
548,435
+2,664
| +0.5% | +$41.7K | ﹤0.01% | 1816 |
|
|
2023
Q4 | $4.94M | Buy |
545,771
+30,674
| +6% | +$205K | ﹤0.01% | 2317 |
|
|
2023
Q3 | $3.29M | Sell |
515,097
-16,546
| -3% | -$143K | ﹤0.01% | 2435 |
|
|
2023
Q2 | $5.9M | Buy |
531,643
+43,046
| +9% | +$540K | ﹤0.01% | 2170 |
|
|
2023
Q1 | $7.5M | Buy |
488,597
+24,779
| +5% | +$545K | ﹤0.01% | 2007 |
|
|
2022
Q4 | $10.3M | Buy |
463,818
+86,700
| +23% | +$1.29M | ﹤0.01% | 1836 |
|
|
2022
Q3 | $6.16M | Buy |
377,118
+39,639
| +12% | +$758K | ﹤0.01% | 2110 |
|
|
2022
Q2 | $4.9M | Buy |
337,479
+37,677
| +13% | +$561K | ﹤0.01% | 2195 |
|
|
2022
Q1 | $5.54M | Buy |
299,802
+8,461
| +3% | +$144K | ﹤0.01% | 2222 |
|
|
2021
Q4 | $6.93M | Buy |
291,341
+7,990
| +3% | +$191K | ﹤0.01% | 2189 |
|
|
2021
Q3 | $6.98M | Buy |
283,351
+140,392
| +98% | +$3.05M | ﹤0.01% | 2215 |
|
|
2021
Q2 | $3.53M | Sell |
142,959
-746
| -0.5% | -$17.4K | ﹤0.01% | 2517 |
|
|
2021
Q1 | $3.13M | Buy |
143,705
+33,902
| +31% | +$830K | ﹤0.01% | 2521 |
|
|
2020
Q4 | $2.8M | Buy |
109,803
+1,935
| +2% | +$56.4K | ﹤0.01% | 2488 |
|
|
2020
Q3 | $3.04M | Buy |
+107,868
| New | +$3.12M | ﹤0.01% | 2320 |
|
Other funds holding RNAM
Charles Schwab's RNAM Position: Q1 2026 in Review
Charles Schwab sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,181,661 shares — an estimated $85.2M sold.
Charles Schwab first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $85.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Charles Schwab reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Charles Schwab sold 1,181,661 Avidity Biosciences shares in Q1 2026, an estimated $85.2M.
- Charles Schwab first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- Charles Schwab's Avidity Biosciences position peaked at $85.2M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.